A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2
about
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virusTMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike proteinSevere acute respiratory syndrome coronavirus-like virus in Chinese horseshoe batsThe SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterizationAnimal models for SARS and MERS coronavirusesStructural Analysis of Major Species Barriers between Humans and Palm Civets for Severe Acute Respiratory Syndrome Coronavirus InfectionsCrystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptorCrystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptorA crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injurySevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionHuman monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutantsYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptorReceptor-binding domain as a target for developing SARS vaccines.Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era.Bat origin of human coronaviruses.Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS.Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals.Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groupsIdentification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathwayIdentification of a new region of SARS-CoV S protein critical for viral entryStructure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion proteinNeutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyImmunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.Structure, Function, and Evolution of Coronavirus Spike Proteins.Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike proteinRecombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human.Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccineSubstitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibodySingle amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
P2860
Q24337838-5346334C-3422-4402-BE5B-0118C507CB28Q24339582-C7CE9356-9BE1-44A2-948A-28C87FED26B6Q24536078-1D303CB0-9F31-4B35-8088-517681FE7E8FQ24817089-E3DAF757-43F3-46DC-8DA0-1F4078F7A1DCQ26799857-EABE5D0A-A628-4A23-A986-8E44A7A7DB22Q27650493-5F85A4D0-64E9-4AA8-88E3-C828208849DEQ27658120-D5D64E60-1345-4A6F-8898-D62D25E8E779Q27670427-954CCA38-BBDD-4608-90A1-78099ECCAA56Q28260798-01D18E45-E719-492E-98DD-EE2AA6494839Q28383088-BBBCE694-B36A-4179-BBFD-004367D3974FQ28768526-7D8F87FC-09C1-41CF-9171-7B38398CE8E3Q30218075-F71474FA-E6ED-4859-93ED-D20D0BEEAA19Q30219701-F528514F-25CE-491B-8D10-25C87B533B9BQ30353170-EF14F1A9-B660-44D9-B7DF-203B04A6ED27Q30354466-AC140207-A377-48B5-B9F4-DA0D1FB9017AQ30360085-DA071467-20B8-4AA1-B5A1-606ADD7AF814Q30382750-76BB85C7-38E4-49D9-8936-3681B883DC01Q30401512-F2F88400-088A-4FB2-AFE4-3BD2E91B2F8BQ30432706-10B50F4C-6514-4AE3-9A32-C3E0D06196C9Q33210858-454DA50C-FA7D-4635-9446-43012B2FFED0Q33239031-85AEA209-E40D-4C48-B8D8-286EF8F9297FQ33242774-56083065-E282-4FF5-A5C0-9DBB1E3B18C7Q33248093-FFA6C06C-417B-40F8-A3E2-30D52032F39EQ33259340-8A582DE8-873D-4852-8011-04EC2A9BD000Q33382958-11795B48-66A0-4BEE-A1A1-E2893A1E21D5Q33383237-75B28F71-3059-40CD-9C25-340AC7925389Q33512190-9DD7B40C-209C-493A-AA41-F4C3321B9A0FQ33581892-C55711E3-5E87-4BD1-B3D9-24C941D90A62Q33688229-D94BD6AD-1136-4A3B-AE83-E2437A4ADD72Q33695621-2FBF7BE4-3E2E-4F51-851B-455697124F10Q33756740-D5EE4EFD-C6CE-4AAF-AC96-EB95F6B8A69DQ33760875-5616A0BE-22D5-4EDA-B338-CBF9ABB3BE44Q33780455-C1F6EA16-EDB4-4CEE-B8A5-E8F2082D43FAQ33788831-8190174C-D396-4442-84A4-ED7C8323FA3DQ33834543-AEDA4B06-EC73-4ADD-9204-A2BB005AC35CQ33841118-1DCA8241-5B9A-4AB0-A199-7B10DE238178Q33849474-323BA93A-255F-4EA9-A59A-D417870A7FC8Q33863306-FE69E769-6E52-4947-B23F-2BF46A1E6777Q33897964-2A7CA408-7452-4D61-865E-6822594B06BBQ33987417-60A93193-E5DE-46CF-807A-9355E21D6F95
P2860
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@ast
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@en
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@nl
type
label
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@ast
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@en
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@nl
prefLabel
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@ast
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@en
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@nl
P2093
P2860
P356
P1476
A 193-amino acid fragment of t ...... ngiotensin-converting enzyme 2
@en
P2093
Hyeryun Choe
Michael J Moore
Swee Kee Wong
P2860
P304
P356
10.1074/JBC.C300520200
P407
P577
2004-01-30T00:00:00Z